TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: To provide evidence for p53 activation at the molecular level, we performed bulk RNA-seq on CML CD34+ cells treated with these drugs for 24 or 72 hrs (Supplementary Data 4) and, in parallel, we identified p53 targets in CML cells by ChIP-sequencing (Supplementary Fig. 3c; Supplementary Data 5).